Edition:
United Kingdom

Theratechnologies Inc (TH.TO)

TH.TO on Toronto Stock Exchange

8.34CAD
8:59pm GMT
Change (% chg)

$0.78 (+10.32%)
Prev Close
$7.56
Open
$7.74
Day's High
$8.40
Day's Low
$7.30
Volume
685,066
Avg. Vol
169,088
52-wk High
$14.75
52-wk Low
$6.72

Latest Key Developments (Source: Significant Developments)

Trogarzo Phase III Data Analysis Presented At HIV Drug Therapy Glasgow 2018
Tuesday, 30 Oct 2018 

Oct 30 (Reuters) - Theratechnologies Inc ::TROGARZO® PHASE III DATA ANALYSIS PRESENTED AT HIV DRUG THERAPY GLASGOW 2018: PATIENTS NOT ACHIEVING PRIMARY ENDPOINT AT DAY 7 EXPERIENCED CLINICAL BENEFIT BY END OF STUDY.THERATECHNOLOGIES INC - OF 40 PATIENTS ENROLLED IN PHASE III CLINICAL TRIAL, ONLY SEVEN DID NOT ACHIEVE PRIMARY ENDPOINT..THERATECHNOLOGIES INC - PATIENTS IN THE STUDY WHO DID NOT ACHIEVE PRIMARY ENDPOINT EVENTUALLY DID EXPERIENCE CLINICAL BENEFITS DURING STUDY..  Full Article

Theratechnologies Reports Q3 Earnings Per Share C$0.00
Thursday, 4 Oct 2018 

Oct 4 (Reuters) - Theratechnologies Inc ::THERATECHNOLOGIES ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER OF 2018.Q3 EARNINGS PER SHARE C$0.00.Q3 REVENUE C$17.71 MILLION VERSUS I/B/E/S VIEW C$16.8 MILLION.Q3 EARNINGS PER SHARE VIEW C$-0.01 -- THOMSON REUTERS I/B/E/S.  Full Article

Theratechnologies Q3 Loss Per Share C$0.04
Thursday, 4 Oct 2018 

Oct 4 (Reuters) - Theratechnologies Inc ::THERATECHNOLOGIES ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER OF 2018.Q3 LOSS PER SHARE C$0.04.Q3 REVENUE C$17.71 MILLION VERSUS I/B/E/S VIEW C$16.8 MILLION.Q3 EARNINGS PER SHARE VIEW C$-0.01 -- THOMSON REUTERS I/B/E/S.  Full Article

Theratechnologies Q2 Loss Per Share C$0.03
Thursday, 5 Jul 2018 

July 5 (Reuters) - Theratechnologies Inc ::THERATECHNOLOGIES ANNOUNCES FINANCIAL RESULTS FOR THE SECOND QUARTER OF 2018.Q2 SALES ROSE 23.1 PERCENT TO C$12.3 MILLION.Q2 LOSS PER SHARE C$0.03.  Full Article

Theratechnologies Submits Novel Single-Vial Formulation Of Egrifta For FDA Approval
Wednesday, 4 Jul 2018 

July 4 (Reuters) - Theratechnologies Inc ::THERATECHNOLOGIES SUBMITS NOVEL SINGLE-VIAL FORMULATION OF EGRIFTA® (TESAMORELIN FOR INJECTION) FOR FDA APPROVAL.THERATECHNOLOGIES INC - FILED SUPPLEMENTAL NEW DRUG APPLICATION WITH FDA FOR A SINGLE-VIAL FORMULATION OF EGRIFTA.  Full Article

Theratechnologies Announces US$50 Mln Bought Deal Offering Of Certain Notes
Wednesday, 30 May 2018 

May 30 (Reuters) - Theratechnologies Inc ::THERATECHNOLOGIES ANNOUNCES US$50 MILLION BOUGHT DEAL OFFERING OF 5.75% CONVERTIBLE UNSECURED SENIOR NOTES.THERATECHNOLOGIES - INTENDS TO USE PROCEEDS OF OFFERING TO FUND PAYMENTS DUE UNDER AMENDMENT OF EMD SERONO TERMINATION AGREEMENT.  Full Article

FDA Releases Theratechnologies From Post-Approval Commitments Related To EGRIFTA
Tuesday, 1 May 2018 

May 1 (Reuters) - Theratechnologies Inc ::FDA RELEASES THERATECHNOLOGIES FROM POST-APPROVAL COMMITMENTS RELATED TO EGRIFTA® (TESAMORELIN FOR INJECTION).THERATECHNOLOGIES - FDA DETERMINED LARGE-SCALE POST-APPROVAL TRIALS NO LONGER REQUIRED AS CURRENT LABELING ADEQUATELY REFLECTS SAFETY PROFILE OF EGRIFTA.THERATECHNOLOGIES - FOR YEAR ENDED NOV 30, 2017, CO ESTIMATED POST-APPROVAL COMMITMENTS WILL REQUIRE $13 MILLION INVESTMENT, WHICH WILL NO LONGER BE NEEDED.  Full Article

Theratechnologies Reports Q1 Loss Per Share C$0.04
Thursday, 5 Apr 2018 

April 5 (Reuters) - Theratechnologies Inc ::THERATECHNOLOGIES ANNOUNCES FINANCIAL RESULTS FOR FIRST QUARTER OF 2018.THERATECHNOLOGIES INC <<>> Q1 REVENUE C$10.22 MLN VS I/B/E/S VIEW C$10.7 MLN.THERATECHNOLOGIES INC <<>> Q1 SHR LOSS C$0.04.THERATECHNOLOGIES - AS AT FEB 28, CASH, BONDS AND MONEY MARKET FUNDS AMOUNTED TO $32.5 MLN COMPARED TO $32.9 MLN AT END OF PREVIOUS FISCAL YEAR.  Full Article

Theratechnologies Announces FDA Approval Of Trogarzo (Ibalizumab-Uiyk) Injection
Tuesday, 6 Mar 2018 

March 6 (Reuters) - Theratechnologies Inc ::THERATECHNOLOGIES ANNOUNCES FDA APPROVAL OF BREAKTHROUGH THERAPY, TROGARZO™ (IBALIZUMAB-UIYK) INJECTION, THE FIRST HIV-1 INHIBITOR AND LONG-ACTING MONOCLONAL ANTIBODY FOR MULTIDRUG RESISTANT HIV-1.  Full Article